Five years of local control of subscapularis aggressive fibromatosis managed by surgery and imatinib: a case report

Journal of Medical Case Reports

Abdellatif Benider¹  Souha Sahraoui¹  Hassan Jouhadi¹  Nezha Tawfiq¹  Zineb Bouchbika¹  Amina Taleb¹  Hamza Jabir¹  Nadia Benchakroun¹  Abou Dao¹ 

[1] Centre Mohammed VI pour le Traitement des Cancers, CHU Ibn Rochd, Casablanca, Morocco

关键词: Surgery;    Subscapularis;    Recurrence;    Local control;    Imatinib;    Aggressive fibromatosis;   

Others  :  1180937
DOI  :  10.1186/1752-1947-8-416

 received in 2014-06-20, accepted in 2014-10-07,  发布年份 2014

【 摘 要 】

Introduction

Imatinib, a tyrosine kinase inhibitor, is a major therapeutic option for the management of unresectable aggressive fibromatosis. Unfortunately, for most patients of low or very low average income countries, surgery often is the first treatment option. This is related to unavailability of chemotherapy or targeted therapy, and to a lack of financial resources or surgeons’ lack of knowledge of other therapeutic options.

Case presentation

In 2010, a 26-year-old Moroccan man was referred to our oncology and radiotherapy center by his surgeon for the management of a recurrent tumor of his right subscapularis muscle. Before his assessment in our center, two resections were performed by his surgeon after performing an incision biopsy and magnetic resonance imaging. Postoperative magnetic resonance imaging was performed and showed a right axillary nodule size 2.1cm regarding a collection with a residual tumor. We decided to administer imatinib 400mg daily by mouth. Clinical and magnetic resonance imaging evaluation were performed regularly and reported a stable tumor. We reported no adverse side effects to imatinib regarding Common Terminology Criteria for Adverse Events grading.

Conclusions

Recurrences are high during aggressive fibromatosis management. Systemic treatment with imatinib for unresectable or recurrent tumors with positive c-KIT could be the best therapeutic option. In our case report, the patient was stabilized with imatinib for 30 months and he had a very good quality of life.

【 授权许可】

   
2014 Dao et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Knechtel G, Stoeger H, Szkandera J, Dorr K, Beham A, Samonigg H: Desmoid tumor treated with polychemotherapy followed by imatinib: a case report and review of the literature. Case Report Oncol 2010, 3(2):287-293.
• [2]Wanjeri JK, Opeya CJ: A massive abdominal wall desmoid tumor occurring in a laparotomy scar: a case report. World J Surg Oncol 2011, 9:35. BioMed Central Full Text
• [3]Siddharth BJ, Peter SR, Franklin S, Scott O, Ivy P: Current perspectives on desmoid tumors: the Mayo Clinic approach. Cancer 2011, 3:3143-3155. doi:10.3390/cancers3033143
• [4]Okuno SH, Edmonson JH: Combination chemotherapy for desmoid tumors. Cancer 2003, 97:1134-1135.
• [5]Veridiana PC, Keohan ML, D’Adamo DR, Antonescu CR, Brennan MF, Singer S, Ahn LS, Maki RG: Clinical outcomes of systemic therapy for patients with deep fibromatoses (desmoid tumors). Cancer 2010, 116(9):2258-2265. doi:10.1002/cncr.25089
• [6]Dufresne A, Bertucci F, Penel N, Le Cesne A, Bui B, Tubiana-Hulin M, Ray-Coquard I, Cupissol D, Chevreau C, Perol D, Goncalves A, Jimenez M, Bringuier PP, Blay JY: Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis. Br J Cancer 2010, 103:482-485.
• [7]Mace J, Biermann JS, Sondak V, McGinn C, Hayes C, Dafydd T, Baker L: Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002, 95(11):2373-2379.
• [8]Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, Hirte H, Cresta S, Koslin DB, Corless CL, Dirnhofer S, van Oosterom AT, Nikolova Z, Dimitrijevic S, Fletcher JA: Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006, 24(7):1195-1203.
• [9]Chugh R, Maki RG, Thomas DG, Reinke D, Wathen JK, Patel S, Priebat DA, Meyers PA, Benjamin RS Baker LH: A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2006, 24:9515. No 18S (June 20 Supplement)
• [10]Fayette J, Dufresne A, Penel N, Le Cesne A, Bui BN, Tubiana-Hulin M, Guillemet C, Chabaud S, Jimenez M, Blay JY: Imatinib for the treatment of aggressive fibromatosis/desmoid tumors (AF/DT) failing local treatment: updated outcome and predictive factors for progression free survival. A FNCLCC French Sarcoma group-GETO trial. Annual meeting proceedings. J Clin Oncol 2006., 25(18S) Abstract 1006. ASCO
• [11]Skubitz KM, Manivel JC, Clohisy DR, Frolich JW: Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors. Cancer Chemother Pharmacol 2009, 64(3):635-640.
• [12]Penel N, Le Cesne A, Bui BN, Perol D, Brain EG, Ray-Coquard I, Guillemet C, Chevreau C, Cupissol D, Chabaud S, Jimenez M, Duffaud F, Piperno-Neumann S, Mignot L, Blay J-Y: Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French sarcoma group phase II trial with a long-term follow-up. Ann Oncol 2011, 22(2):452-457.
• [13]Molloy AP, Hutchinson B, O’Toole GC: Extra-Abdominal Desmoid Tumours: A Review of the Literature. Volume 2012. Hindawi Publishing Corporation Sarcoma; :9. Article ID 578052, doi:10.1155/2012/578052